Iambic Presents Preclinical Data for CDK2/4 Inhibitor IAM-C1 and Brain-Penetrant KIF18A Inhibitor IAM217 at 2026 EORTC-NCI-AACR Symposium
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Iambic (IAM) announced two preclinical poster presentations on IAM-C1 and IAM217 at the EORTC-NCI-AACR Symposium, held November 18–20 in Barcelona. IAM-C1, a dual CDK2/4 inhibitor, showed activity on its own across models dependent on either or both targets. In a patient-derived breast cancer model resistant to CDK4/6 inhibitors, it achieved 78% tumor growth inhibition versus 24% with palbociclib. In rats, IAM-C1 reduced neutrophils, a type of white blood cell, by a mean of 13% versus 48% with combined selective CDK2 and CDK4 inhibitors, despite higher exposure multiples.
IAM217, a brain-penetrant KIF18A inhibitor, achieved approximately 90% regression in an intracranial breast cancer model. Both candidates are wholly owned. Iambic received a Safe-to-Proceed Letter for an IAM217 Phase 1/2 trial and expects to submit an investigational new drug application for IAM-C1 in Q4 2026.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointIAM217 Phase 1/2 trial received a Safe-to-Proceed Letter.
- Minor pointIAM217 intracranial breast cancer model showed approximately 90% regression.
- Minor pointIAM-C1 in a resistant patient-derived breast cancer model achieved 78% tumor growth inhibition versus 24% with palbociclib.
- Minor point. Forward-looking: it has not happened yet and may not happen.IAM-C1 filing is expected by Iambic in Q4 2026 to seek permission to begin human studies.
- Minor pointIAM-C1 neutrophil counts in rats fell by a mean of 13% at 1.3–1.4x exposure multiples across two studies, versus 48% with combined selective CDK2 and CDK4 inhibitors at 0.65–0.75x and 69% with palbociclib.
11 minor points
- Minor pointIAM-C1 as a single agent achieved 138%, 97% and 94% tumor growth inhibition in the MCF-7, OVCAR-3 and MFE-296 models, respectively.
- Minor pointIAM-C1 in the MFE-296 model inhibited tumor growth more than single-agent CDK2, CDK4 or CDK4/6 inhibitors and comparably to combined selective CDK2 and CDK4 inhibition.
- Minor pointIAM217 at 60 mg/kg once daily for approximately 21 days showed antitumor activity in breast, ovarian, colon and osteosarcoma models, with regressions in multiple models.
- Minor pointIAM217 in ovarian cancer models showed dose-dependent tumor growth inhibition and was well tolerated at all dose levels tested.
- Minor pointIAM-C1 with fulvestrant or imlunestrant showed greater antitumor activity than either partner drug alone in the MCF-7 model.
- Minor pointIAM217 with eribulin showed synergy in ovarian and triple-negative breast cancer cell lines.
- Minor pointIAM217 unbound drug concentrations in plasma and cerebrospinal fluid exceeded the free IC90, a 90% inhibition threshold, for more than 24 hours in the brain metastasis model.
- Minor pointIAM217 cell tests showed growth inhibition in OVCAR-3 ovarian cancer cells with high chromosomal instability at a half-maximal inhibitory concentration of 24 nM, while sparing MCF-7 cells with low chromosomal instability and bone marrow blood-cell precursors.
- Minor pointIAM217 preclinical screening found no signal in a mini-Ames test for mutations and showed selectivity in protein screens.
- Minor pointIAM-C1 biochemical tests showed half-maximal inhibition below 1 nM for both CDK2/cyclin E1 and CDK4/cyclin D1.
- Minor pointIAM-C1 cell tests showed half-maximal inhibition of RB protein phosphorylation at 18–19 nM and of cell proliferation at 40–100 nM.
Negative
- Minor pointIAM-C1 off-target binding met the screening criterion for four non-mutant kinases at 30 nM.
Key Figures
- Biochemical IC50
- Below 1 nM
- IAM-C1 inhibition of CDK2/cyclin E1 and CDK4/cyclin D1
- Tumor growth inhibition
- 138% (MCF-7), 97% (OVCAR-3), 94% (MFE-296)
- IAM-C1 as a single agent in xenograft models
- Patient-derived xenograft TGI
- 78% vs. 24%
- IAM-C1 vs. palbociclib in the ST4316B ER+/HER2- breast cancer model
- Mean neutrophil count reduction
- 13% vs. 48% and 69%
- IAM-C1 at exposure multiples of 1.3–1.4x; combined selective CDK2 and CDK4 inhibitors at 0.65–0.75x and palbociclib, respectively
- Cell growth IC50
- 24 nM vs. >10,000 nM
- IAM217 in CIN-high OVCAR-3 vs. CIN-low MCF-7 cells
- Intracranial tumor regression
- Approximately 90%
- IAM217 in an intracranial JIMT-1 breast cancer model
- Exposure above free IC90
- More than 24 hours
- Unbound IAM217 plasma and cerebrospinal fluid concentrations
Historical Context
-
IAM217 received a Safe-to-Proceed Letter; IAM-C1 IND submission was expected in Q4 2026.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
ic50 technical
patient-derived xenograft medical
mini-ames assay technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- IAM-C1, a selective dual CDK2/4 inhibitor, showed single-agent antitumor activity across CDK2-, CDK4- and CDK2/CDK4-dependent models, including a CDK4/6 inhibitor-resistant breast cancer patient-derived xenograft model
- IAM-C1 produced smaller neutrophil reductions than combined selective CDK2 and CDK4 inhibition, despite higher exposure multiples
- IAM217, a brain-penetrant KIF18A inhibitor, drove deep regressions across multiple preclinical models with approximately
90% regression in an intracranial breast cancer model - Both wholly owned drug candidates were designed using Iambic’s AI-driven, molecular superintelligence platform and are advancing toward the clinic, with a Safe-to-Proceed Letter received for a Phase 1/2 trial for IAM217 and an IND submission for IAM-C1 anticipated in Q4
SAN DIEGO, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Iambic (Nasdaq: IAM), a clinical-stage life sciences and technology company developing novel medicines using its AI-driven platform, today announced two preclinical poster presentations at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), known as the Triple Meeting, taking place November 18–20, 2026 in Barcelona.
The posters present preclinical data for IAM-C1, a selective dual CDK2/4 inhibitor in development for HR+/HER2- breast cancer and CCNE1-amplified cancers, and IAM217, a brain-penetrant KIF18A inhibitor in development for cancers with chromosomal instability (CIN). Both wholly owned drug development candidates were designed using Iambic’s molecular superintelligence platform, which integrates Enchant® and NeuralPLexer®, its flagship AI technologies for multimodal endpoint and protein-ligand structural predictions, with automated chemistry and biology experimentation.
“IAM-C1 and IAM217 are Iambic’s second and third drug development candidates and demonstrate what our molecular superintelligence platform is designed to do: discover and advance differentiated molecules to address urgent unmet patient need,” said Tom Miller, PhD, Co-Founder and CEO, Iambic. “For IAM-C1, it meant dual CDK2 and CDK4 activity while sparing other CDKs associated with dose-limiting toxicities. For IAM217, it meant selective KIF18A inhibition with brain penetrance. The preclinical data presented at ENA reflect both design goals, and we look forward to advancing these programs to and through clinic.”
“Resistance to CDK4/6 inhibitors remains a key limitation in HR+/HER2- breast cancer, and increased CDK2 signaling through cyclin E is one route to that resistance,” said Pete Olson, PhD, Chief Scientific Officer, Iambic. “In our studies, IAM-C1 was active in models driven by CDK2, CDK4 or both, including a patient-derived model from a patient previously treated with abemaciclib and palbociclib. With IAM217, we saw selective activity against chromosomally unstable tumor cells in vitro and deep regressions in vivo, including in an intracranial model. We are encouraged by these preclinical data and look forward to submitting an IND for IAM-C1 later this year and initiating the Phase 1/2 trial for IAM217.”
POSTER PRESENTATIONS
Title: IAM-C1, a Potent and Selective Dual CDK2/CDK4 Inhibitor, Demonstrates Robust Antitumor Activity and a Favorable Preclinical Tolerability Profile
Abstract: 234 | Poster: PB-129 | Session: Molecular Targeted Agents | November 19, 2026 | Exhibition Hall, CCIB| Presenter: Pete Olson, Iambic
Summary:
- IAM-C1 inhibited CDK2/cyclin E1 and CDK4/cyclin D1 with biochemical IC50 values below 1 nM. Across a broad kinome panel at 30 nM, four non-mutant off-target kinases met the binding-hit criterion.
- In cancer cell lines with distinct CDK dependencies (MCF-7, CDK4; OVCAR-3, CDK2; MFE-296, CDK2/CDK4), IAM-C1 suppressed RB phosphorylation (IC50 18–19 nM), inhibited proliferation (IC50 40–100 nM) and depleted S-phase cells.
- As a single agent, IAM-C1 achieved tumor growth inhibition (TGI) of
138% in MCF-7,97% in OVCAR-3 and94% in MFE-296 xenograft models. In the CDK2/CDK4 co-dependent MFE-296 model, TGI with IAM-C1 exceeded that of single-agent CDK2, CDK4 and CDK4/6 inhibitors and was comparable to a combination of selective CDK2 and CDK4 inhibitors.In the ST4316B ER+/HER2- breast cancer patient-derived xenograft model, established from a patient previously treated with abemaciclib and palbociclib, IAM-C1 achieved78% TGI versus24% with palbociclib. - In the MCF-7 model, IAM-C1 combined with fulvestrant or imlunestrant produced significantly greater antitumor activity than either selective estrogen receptor degrader alone.
- In rats, IAM-C1 reduced neutrophil counts by a mean of
13% at exposure multiples of 1.3–1.4x across two studies, compared with48% for combined selective CDK2 and CDK4 inhibitors at 0.65–0.75x and69% for palbociclib.
Title: IAM217: a Novel, Brain-penetrant KIF18A Inhibitor for Targeting Chromosomal Instability in Cancer
Abstract: 330 | Poster: PB-122 | Session: New Drugs | November 20, 2026 | Exhibition Hall, CCIB | Presenter: Jill Hallin, Iambic
Summary:
- IAM217 inhibited growth of CIN-high OVCAR-3 ovarian cancer cells (IC50 24 nM) while sparing CIN-low MCF-7 cells (IC50 >10,000 nM) and bone marrow hematopoietic progenitor cells (IC50 7,700 nM to >10,000 nM). Anti-proliferative activity tracked with mitotic arrest.
- IAM217 was negative in a mini-Ames assay, showed a clean kinesin and kinome selectivity screen, and achieved CNS exposure in rodents.
- Once-daily oral dosing in ovarian cancer xenograft models produced dose-dependent plasma and tumor exposure that correlated with dose-dependent tumor growth inhibition and modulation of the mitotic marker phospho-histone H3. IAM217 was well tolerated at all dose levels tested.
- At 60 mg/kg once daily for approximately 21 days, IAM217 showed antitumor activity across a panel of breast cancer cell line-derived and patient-derived xenograft models, as well as ovarian, colon and osteosarcoma models, with deep regressions in multiple models.
- In an intracranial JIMT-1 breast cancer model of brain metastasis, IAM217 achieved approximately
90% regression. Unbound plasma and cerebrospinal fluid concentrations exceeded the free IC90 for more than 24 hours. - In vitro, IAM217 combined with eribulin showed synergy in Kuramochi (ovarian cancer) and HCC1187 (triple-negative breast cancer) cell lines.
About Iambic
Iambic’s mission is to make better technology for better medicines. By utilizing molecular superintelligence — integrating proprietary AI with automated, scalable chemistry and biology experimentation — our platform is designed to address the totality of drug discovery and development. We believe the utility of our platform is demonstrated by the discovery of IAM1363, a novel drug candidate advanced to clinic in approximately two years, along with a diverse preclinical pipeline. Our leading AI technologies include Enchant® and NeuralPLexer® for multimodal endpoint prediction designed to improve the speed, precision, and success rates of drug discovery and clinical development. At Iambic, we are building an engine that is designed to power the future of medicine. | iambic.ai
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements. Words such as “anticipate,” “believe,” “continue,” “could,” “designed,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “should,” “will” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to: statements regarding the potential therapeutic effects of IAM-C1 and IAM217, the potential tolerability of IAM-C1 and IAM217, the potential for IAM-C1 and IAM217 to be differentiated from other therapies, the anticipated timing of an IND submission for IAM-C1, Iambic’s plans to advance IAM-C1 and IAM217 into clinical development, and the capabilities of Iambic’s platform. These statements are based on numerous assumptions and involve substantial risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievement to be materially different from the information expressed or implied by these forward-looking statements, including that results of preclinical studies may not be predictive of results in clinical trials; comparisons across separate studies or to other compounds may not be reliable indicators of relative performance; that IAM-C1 or IAM217 may demonstrate unexpected safety or tolerability findings in humans; and that IND submissions, regulatory clearances and trial initiations may not occur on the anticipated timelines or at all. These and other risks are described more fully under “Risk Factors” in Iambic’s final prospectus relating to its initial public offering filed with the Securities and Exchange Commission pursuant to Rule 424(b) on October 14, 2026, Iambic’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, to be filed with the Securities and Exchange Commission, and in Iambic’s subsequent filings with the Securities and Exchange Commission. The forward-looking statements in this press release speak only as of the date of this press release, and you should not rely on them as representing Iambic’s views as of any subsequent date. Iambic undertakes no obligation to update these forward-looking statements, or the reasons actual results could differ from those projected, except as required by law.
Contacts
Media:
Amanda Guisbond,
Head of Communications, Iambic
amanda.guisbond@iambic.ai
Investors:
Tiao Guan,
Sr. Director, FP&A and Investor Relations, Iambic
tiao.guan@iambic.ai
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.